New UK-first trial to screen 20000 children for type 1 diabetes – DiabetesTimes.co.uk

A trial screening programme for type 1 diabetes that could transform the way the condition is identified and managed in its earliest stages, has opened for recruitment.
The first programme of its kind in the UK will identify children at high risk of type 1 diabetes, laying the groundwork for the development of a UK-wide screening programme.
Launched on World Diabetes Day, the EarLy Surveillance for Autoimmune diabetes (ELSA) programme aims to recruit 20,000 children, aged three to 13 years old, to assess their risk of developing type 1 diabetes.
Funded by Diabetes UK and JDRF, ELSA will provide crucial insights into effective and acceptable ways to screen large numbers of children in the UK, and support those at high risk and their families to ensure the earliest, safest diagnosis possible.
Those identified as high risk could also gain access to clinical trials testing the newest innovations in type 1 diabetes treatment, that could prevent or delay the condition.
The national research team, led by researchers at the University of Birmingham, will assess children’s risk of type 1 diabetes through a combination of finger prick and venous blood tests.
The team will test for markers in the blood, called autoantibodies – tools used by the immune system to earmark insulin-producing cells for destruction.
Autoantibodies are associated with the development of type 1 diabetes, and can appear in the blood years, or sometimes decades, before people begin to experience any symptoms.
Children found to be at risk and their families will be offered support and education – including information on symptoms and management – to help prepare them for the diagnosis of type 1 diabetes.
Families will also be offered the opportunity to be followed up in the long-term to enable closer monitoring and potentially to start insulin treatment sooner.
Research in Europe and the US has found that the extra support and monitoring screening programmes can offer dramatically reduces the risk of being diagnosed in DKA.
While type 1 diabetes is currently managed using insulin, there are new immunotherapy treatments on the horizon that could prevent or delay the condition.
Children found to be at high risk could be invited to take part in research testing these treatments.
One such treatment, teplizumab, which has been found to delay a diagnosis of type 1 diabetes by up to three years and is currently being reviewed for use in the UK.
Through a series of interviews with families and healthcare professionals, the team aim to understand the most effective way to deliver a future screening programme.
These insights will be critical in making the case for widespread routine screening for type 1 diabetes in the UK.
Parth Narendran, Professor of Diabetes Medicine, and Dr Lauren Quinn, Clinical Research Fellow at the University of Birmingham, said: “As general population screening programmes for type 1 diabetes emerge around the world, we need to explore how best to screen children here in the UK.
“The ELSA study will ask important questions about the best ways to recruit, and explore the experiences of families who take part.”
They added: “Screening children can reduce their risk of DKA at diagnosis around five-fold, and can help them and their families settle into the type 1 diagnosis better.
“We know the value of identifying people at risk of type 1 diabetes and we have the tools to do so – now we need to understand how best to implement them in the UK.”
They concluded: “We are extremely grateful to our funders, Diabetes UK and JDRF. We hope ELSA will lead to the roll-out of a type 1 diabetes early detection programme for children in the UK and encourage families with children at a suitable age to consider taking part. To find out more about the ELSA study and to sign up, visit elsadiabetes.nhs.uk/take-part.”
Photo by Karolina Grabowska on Pexels
Register an account or login to comment
Diabetes UK issues latest guidance on coronavirus
People with diabetes urged to be ‘particularly stringent’ amid COVID-19 pandemic
NHS Drug Tariff approval for FreeStyle Libre System
Updated metformin and B12 guidance published
Criticism over Eatwell Plate amid calls for low carb approach
Type 1 man no longer requires insulin
Man commended for living with diabetes for 80 years
Warning over Lucozade sugar reduction
FreeStyle® Libre 2 includes optional real-time alarms
Novo Nordisk UK launches Ozempic® (semaglutide)
Deadline looms for Rowan Hillson Award 2023
Beraprost sodium delays the decline of glomerular filtration rate in people with diabetic nephropathy
Cardiovascular risk factors higher in people with diabetes, latest research claims
New UK-first trial to screen 20,000 children for type 1 diabetes
Artificial pancreas successfully trialled for use by people with type 2 diabetes
Diabetes Times launches new podcast
Diabetes foot disease hospital admissions significantly on the rise, research reveals
Beta cell mass important for glycaemic control in people with type 1 diabetes
HbA1c screening reduces diabetes diagnosis delay in middle-aged adults
New artificial pancreas technology set to change the lives of people unable to manage their type 1 diabetes
Consultant in Diabetes
Consultant in Diabetes and Endocrinology
Diabetes Specialist Nurse
Diabetes Inpatient Specialist Nurse
Diabetes Specialist nurse
Clinical Lead – Diabetes
Paediatric Diabetes Specialist Nurse
Diabetic Eye Screener Grader
Specialist Diabetes Dietitian
Highly Specialised Diabetes Nurse

The Diabetes Times © 2023

source